<DOC>
	<DOCNO>NCT00025532</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver tumor-killing substance without harm normal cell . This may effective treatment gastrointestinal cancer . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody therapy treat patient gastrointestinal cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Treating Patients With Gastrointestinal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine biodistribution biokinetics iodine I 131-labeled monoclonal antibody CC49-delta CH2 patient gastrointestinal adenocarcinoma . II . Determine human anti-human monoclonal antibody response patient treated drug . OUTLINE : Patients receive iodine I 131-labeled monoclonal antibody CC49-delta CH2 ( 131I MOAB CC49-delta CH2 ) IV 5-10 minute day 0 . Patients also receive unlabeled monoclonal antibody CC49-delta CH2 IV 5 minute follow 131I MOAB CC49-delta CH2 IV 5-10 minute day 28 . Patients follow weekly 4 month every 3 month 1 year . PROJECTED ACCRUAL : A total 25 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma esophagus , stomach , pancreas , colon , rectum More 30 % positively immunoreactive monoclonal antibody CC49 metastatic primary lesion OR TAG72 antigen serum level great 15 Measurable evaluable unresectable metastatic disease CT scan PATIENT CHARACTERISTICS : Age : 19 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC great 3,500/mm3 Platelet count great 150,000/mm3 Hemoglobin great 10 g/dL Hepatic : Bilirubin le 2.0 mg/dL ALT AST less 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) PTT le 37.0 second INR le 2.0 Renal : Creatinine le 2.0 mg/dL Other : No know allergy murine immunoglobulin No iodine allergy No concurrent illness would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must ambulatory able comply study schedule PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine immunoglobulin Chemotherapy : Prior concurrent chemotherapy allow Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>